1
|
Lansink DG, Zogaj D, Veldhuis E, Hess D, Wagenaar FCBM, Visser FW. [Flucloxacillin-induced hypokalemia]. Ned Tijdschr Geneeskd 2024; 168:D6861. [PMID: 38375895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2024]
Abstract
Flucloxacillin-induced hypokalaemia can be progressive and life-threatening, despite of potassium supplementation. In this case description, a high dose of intravenous flucloxacillin was started after a 68-year-old patient presented with an infected knee replacement. After two days, hypokalaemia was noted with an inadequate response to potassium supplementation. It was decided to change antibiotics and increase potassium supplementation, with good results. It is advisable to include monitoring of potassium levels in local treatment protocols when flucloxacillin is prescribed.
Collapse
|
2
|
Puar P, Mistry N, Connelly K, Yan A, Quan A, Teoh H, Pan Y, Verma R, Hess D, Verma S, Mazer C. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 AS A MARKER OF CARDIAC REVERSE REMODELING WITH EMPAGLIFLOZIN: A SECONDARY ANALYSIS OF THE EMPA-HEART CARDIOLINK-6 RANDOMIZED CONTROLLED TRIAL. Can J Cardiol 2022. [DOI: 10.1016/j.cjca.2022.08.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
3
|
Geeraedts F, Luttje M, Visschedijk J, van Hattem M, Hasper HJ, Kohnen R, Loman R, de Goede R, Jansen D, Hess D, Al Naiemi N. Low-Threshold Testing for SARS-CoV-2 (COVID-19) in Long-Term Care Facilities Early in the First Pandemic Wave, the Twente Region, the Netherlands: A Possible Factor in Reducing Morbidity and Mortality. J Appl Gerontol 2022; 41:1802-1811. [PMID: 35543170 PMCID: PMC9127376 DOI: 10.1177/07334648221093050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
During the first wave of the COVID-19 pandemic, there was a shortage of
SARS-CoV-2 diagnostic tests, and testing patients with mild symptoms
(low-threshold testing) was not recommended in the Netherlands. Despite these
guidelines, to protect those who were most at risk, low-threshold testing was
advocated and offered to the majority of long-term care institutions in the
Twente region. In this manner, 144 healthcare workers and
96 residents tested SARS-CoV-2-positive and were isolated before the same
service was provided nationwide by public health services. Strikingly, excess
mortality rate in the Twente region 1 month after the
introduction of this strategy was found to be 62%–89% lower than that in
neighboring regions, which may be explained by this divergent testing strategy.
In an emerging pandemic, early implementation of a liberal testing policy may be
more effective than restricted testing in settings with a high death rate.
Collapse
Affiliation(s)
- Felix Geeraedts
- Laboratory for Medical Microbiology and Public Health, Hengelo, the Netherlands
| | - Mariska Luttje
- Carintreggeland Nursing Homes and Home Care, Hengelo, the Netherlands
| | - Jan Visschedijk
- Carintreggeland Nursing Homes and Home Care, Hengelo, the Netherlands
| | | | - Henk-Jan Hasper
- Trivium Meulenbelt Zorg Nursing Homes and Home Care, Almelo, the Netherlands
| | - Roy Kohnen
- Livio Nursing Homes and Home Care, Enschede, the Netherlands
| | - Rene Loman
- Zorggroep Sint Maarten Nursing Homes and Home Care, Denekamp, the Netherlands
| | - Rudi de Goede
- Liberein Nursing Homes and Home Care, Enschede, the Netherlands
| | - Desiré Jansen
- De Posten Nursing Homes and Home Care, Enschede, the Netherlands
| | - Dorine Hess
- Laboratory for Medical Microbiology and Public Health, Hengelo, the Netherlands
| | - Nashwan Al Naiemi
- Laboratory for Medical Microbiology and Public Health, Hengelo, the Netherlands
| |
Collapse
|
4
|
Geeraedts F, Wertenbroek A, de Klerk J, Prick JJ, Reichman LJA, Hess D, Bosma F, Reimerink J, Skidmore B, Laverman GD. Defining a risk area for tick-borne encephalitis (TBE) in a country where TBE is emerging, the Netherlands, July 2016-October 2020. Ticks Tick Borne Dis 2022; 13:101898. [PMID: 35042080 DOI: 10.1016/j.ttbdis.2022.101898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 12/20/2021] [Accepted: 12/27/2021] [Indexed: 11/30/2022]
Abstract
TBE is an emerging infectious disease in the Netherlands since July 2016, and risk areas have not been defined yet. Until October 2020 twelve autochthonous cases of TBE have been identified. In six of these cases transmission of TBE virus likely occurred in the Twente region, which therefore is the region with the highest case number and risk of contracting the disease. Here we summarize the Twente cases so far and discuss if the Twente region should be considered a risk-area using criteria of traditional TBE endemic countries, and the public health measures that may accompany such designation.
Collapse
Affiliation(s)
- Felix Geeraedts
- Laboratory for Medical Microbiology and Public Health, Hengelo, the Netherlands.
| | - Agnes Wertenbroek
- Department of Neurology, Ziekenhuis Groep Twente, Almelo/Hengelo, the Netherlands
| | - Jabke de Klerk
- Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands
| | - Jan J Prick
- Department of Neurology, Ziekenhuis Groep Twente, Almelo/Hengelo, the Netherlands
| | - Loes J A Reichman
- Department of Neurology, Ziekenhuis Groep Twente, Almelo/Hengelo, the Netherlands
| | - Dorine Hess
- Laboratory for Medical Microbiology and Public Health, Hengelo, the Netherlands
| | - Froukje Bosma
- Laboratory for Medical Microbiology and Public Health, Hengelo, the Netherlands; Public Health Service, Twente, the Netherlands
| | - Johan Reimerink
- Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | | | - Gozewijn D Laverman
- Department of Internal Medicine, Ziekenhuis Groep Twente, Almelo/Hengelo, the Netherlands
| |
Collapse
|
5
|
Ereth MH, Fine J, Stamatatos F, Mathew B, Hess D, Simpser E. Healthcare-associated infection impact with bioaerosol treatment and COVID-19 mitigation measures. J Hosp Infect 2021; 116:69-77. [PMID: 34302883 PMCID: PMC8295046 DOI: 10.1016/j.jhin.2021.07.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 07/15/2021] [Accepted: 07/16/2021] [Indexed: 01/22/2023]
Abstract
BACKGROUND The real-world impact of breathing zone air purification and coronavirus disease 2019 (COVID-19) mitigation measures on healthcare-associated infections is not well documented. Engineering solutions to treat airborne transmission of disease may yield results in controlled test chambers or single rooms, but have not been reported on hospital-wide applications, and the impact of COVID-19 mitigation measures on healthcare-associated infection rates is unknown. AIM To determine the impact of hospital-wide bioaerosol treatment and COVID-19 mitigation measures on clinical outcomes. METHODS The impact of the step-wise addition of air disinfection technology and COVID-19 mitigation measures to standard multi-modal infection control on particle counts, viral and bacterial bioburden, and healthcare-associated infection rates was investigated in a 124-bed hospital (>100,000 patient-days over 30 months). FINDINGS AND CONCLUSION The addition of air disinfection technology and COVID-19 mitigation measures reduced airborne ultrafine particles, altered hospital bioburden, and reduced healthcare-associated infections from 11.9 to 6.6 (per 1000 patient-days) and from 6.6 to 1.0 (per 1000 patient-days), respectively (P<0.0001, R2=0.86). No single technology, tool or procedure will eliminate healthcare-associated infections, but the addition of a ubiquitous facility-wide engineering solution at limited expense and with no alteration to patient, visitor or staff traffic or workflow patterns reduced infections by 45%. A similar impact was documented with the addition of comprehensive, restrictive, and labour- and material-intensive COVID-19 mitigation measures. To the authors' knowledge, this is the first direct comparison between traditional infection control, an engineering solution and COVID-19 mitigation measures.
Collapse
Affiliation(s)
- M H Ereth
- Mayo Clinic College of Medicine, Rochester, MN, USA.
| | - J Fine
- St. Mary's Hospital for Children, Bayside, NY, USA
| | | | - B Mathew
- St. Mary's Hospital for Children, Bayside, NY, USA
| | - D Hess
- SecureAire, Inc, Dunedin, FL, USA
| | - E Simpser
- St. Mary's Hospital for Children, Bayside, NY, USA
| |
Collapse
|
6
|
Luu A, Chowdhury B, Luu V, Pan Y, Quan A, Teoh H, Hess D, Verma S. LOSS OF ENDOTHELIAL CELL-SPECIFIC AUTOPHAGY-RELATED PROTEIN 7 EXACERBATES DOXORUBICIN-INDUCED CARDIOTOXICITY. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
7
|
Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen C. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70. [PMID: 31455773 PMCID: PMC6711992 DOI: 10.1038/s41408-019-0228-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2019] [Revised: 05/20/2019] [Accepted: 05/28/2019] [Indexed: 01/12/2023] Open
Abstract
The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide-dexamethasone can overcome lenalidomide resistance in lenalidomide-refractory multiple myeloma (MM). Twenty-nine patients were included (high-risk cytogenetic aberrations 31%; ≥2 prior therapy lines 93%; lenalidomide-bortezomib double-refractory 34%). Twenty-four patients (83%) had prior bortezomib and 10 (34%) were lenalidomide-bortezomib double-refractory. They received four cycles of nelfinavir 2500 mg/day with standard-dose lenalidomide (25 mg days 1-21) and dexamethasone (40/20 mg days 1, 8, 15, 22). Minor response or better was achieved in 16 patients (55%; 95% CI 36-74%), including 40% of those who were lenalidomide-bortezomib double-refractory, and partial response or better in nine patients (31%; 95% CI 15-51%). Median progression-free survival was 3.4 (95% CI 2.0-4.9) months and median overall survival 21.6 (13.0-50.1) months. Lenalidomide-related pneumonitis, pneumonia, and neutropenic fever occurred, but there were no unexpected adverse events. Peripheral blood mononuclear cells showed a 45% (95% CI 40-51%) reduction in total proteasome activity from baseline and significant induction of unfolded protein response and autophagy. Thus, nelfinavir-lenalidomide-dexamethasone is an active oral combination in lenalidomide-refractory MM.
Collapse
Affiliation(s)
- F Hitz
- Department of Oncology and Hematology, Kantonsspital St.Gallen, St.Gallen, Switzerland.
| | - M Kraus
- Department of Oncology and Hematology, Kantonsspital St.Gallen, St.Gallen, Switzerland
| | - T Pabst
- Department of Medical Oncology, Inselspital, Universitätsspital Bern, Bern, Switzerland
| | - D Hess
- Department of Oncology and Hematology, Kantonsspital St.Gallen, St.Gallen, Switzerland
| | - L Besse
- Department of Oncology and Hematology, Kantonsspital St.Gallen, St.Gallen, Switzerland
| | - T Silzle
- Department of Oncology and Hematology, Kantonsspital St.Gallen, St.Gallen, Switzerland
| | - U Novak
- Department of Medical Oncology, Inselspital, Universitätsspital Bern, Bern, Switzerland
| | - K Seipel
- Department of Medical Oncology, Inselspital, Universitätsspital Bern, Bern, Switzerland
| | - S Rondeau
- SAKK Coordinating Center, Bern, Switzerland
| | - S Stüdeli
- SAKK Coordinating Center, Bern, Switzerland
| | | | | | - U Mey
- Department of Oncology, Kantonsspital Graubünden, Chur, Switzerland
| | - C Driessen
- Department of Oncology and Hematology, Kantonsspital St.Gallen, St.Gallen, Switzerland
| |
Collapse
|
8
|
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Rossi D, Dirnhofer S, Ceriani L, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.78_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Stathis
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - U. Mey
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - S. Schär
- Coordinating Center; SAKK; Bern Switzerland
| | - F. Hitz
- Oncology/Hematology; Kantonsspital St.Gallen; St.Gallen Switzerland
| | - C. Pott
- Medizinischen Klinik II Hämatologie und Internistische Onkologie; Universitätsklinikum Schleswig-Holstein; Campus Kiel Kiel Germany
| | - N. Mach
- Service d'Oncologie; Département d'Oncologie, Hôpitaux Universitaires de Genève; Genève Switzerland
| | - F. Krasniqi
- Medical Oncology; University Hospital of Basel; Basel Switzerland
| | - U. Novak
- Department of Medical Oncology; Inselspital / Bern University Hospital; Bern Switzerland
| | - C. Schmidt
- Department of Medicine III; University of Munich; Munich Germany
| | - K. Hohloch
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - D. Kienle
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - D. Hess
- Oncology/Hematology; Kantonsspital St.Gallen; St.Gallen Switzerland
| | - A. Moccia
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Unterhalt
- Department of Medicine III; University of Munich; Munich Germany
| | | | - S. Hayoz
- Coordinating Center; SAKK; Bern Switzerland
| | - D. Rossi
- Laboratory of Experimental Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - S. Dirnhofer
- Pathologie; Universitätsspital Basel; Basel Switzerland
| | - L. Ceriani
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Bertoni
- Lymphoma Genomics; Institute of Oncology Research; Bellinzona Switzerland
| | - C. Buske
- CCC Ulm; University Hospital Ulm; Ulm Germany
| | - E. Zucca
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - W. Hiddemann
- Department of Medicine III; University of Munich; Munich Germany
| |
Collapse
|
9
|
Hess D, Destors M, Briault A, Jeanjean C, Kelkel E, Pison C, Aguilaniu B. Faut il s’affranchir du mMRC pour évaluer le retentissement symptomatique de la BPCO ? Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Quétant S, Hess D, Aguilaniu B. Les patients atteints de FPI sont-ils toujours traités par un antifibrosant ? Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Aguilaniu B, Briault A, Destors M, Kelkel E, Jeanjean C, Hess D, Pison C. Colibri BPCO : enfance évolutive des charges thérapeutiques. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Andujar P, Kelkel E, Briault A, Jeanjean C, Pernot J, Bertrand D, Hérengt F, Guillaud-Ségard B, Pépin JL, Destors M, Leroy S, Ben-Saidane H, Gonzalez J, Camara B, Debabeche N, Ernesto S, Plaindoux A, Bosc C, Guerder A, Pontier-Marchandise S, Maurel F, Boyer L, Hess D, Burgel PR, Roche N, Aguilaniu B. Prise en charge des patients avec BPCO en consultation en CHU, CHG et en médecine libérale dans l’observatoire Colibri-BPCO. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Hess D, Kelkel E, Pison C, Lorillou M, Gentil B, Pontier-Marchandise S, Guerder A, Marquette CH, Pernot J, Debabeche N, Briault A, Bertrand D, Guillaud-Segard B, Bon F, Destors M, Aguilaniu B. Évolution de la prescription des traitements inhalés chez les patients BPCO après l’étude FLAME (Colibri-BPCO). Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Buscot M, Quétant S, Marquette C, Leroy S, Pradelli J, Lintz F, Boyer G, Harb E, Leheron C, Bertrand D, Maurel F, Perquis G, Belmont L, Appere De Vecchi C, Hess D, Aguilaniu B. Observatoire Colibri-PID : caractéristiques des patients avec une fibrose pulmonaire. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Borstlap WAA, Musters GD, Stassen LPS, van Westreenen HL, Hess D, van Dieren S, Festen S, van der Zaag EJ, Tanis PJ, Bemelman WA. Vacuum-assisted early transanal closure of leaking low colorectal anastomoses: the CLEAN study. Surg Endosc 2017; 32:315-327. [PMID: 28664443 PMCID: PMC5770507 DOI: 10.1007/s00464-017-5679-6] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 06/19/2017] [Indexed: 12/13/2022]
Abstract
Introduction Non-healing of anastomotic leakage can be observed in up to 50% after total mesorectal excision for rectal cancer. This study investigates the efficacy of early transanal closure of anastomotic leakage after pre-treatment with the Endosponge® therapy. Methods In this prospective, multicentre, feasibility study, transanal suturing of the anastomotic defect was performed after vacuum-assisted cleaning of the presacral cavity. Primary outcome was the proportion of patients with a healed anastomosis at 6 months after transanal closure. Secondary, healing at last follow-up, continuity, direct medical costs, functionality and quality of life were analysed. Results Between July 2013 and July 2015, 30 rectal cancer patients with a leaking low colorectal anastomosis were included, of whom 22 underwent neoadjuvant radiotherapy. Median follow-up was 14 (7–29) months. At 6 months, the anastomosis had healed in 16 (53%) patients. At last follow-up, anastomotic integrity was found in 21 (70%) and continuity was restored in 20 (67%) patients. Non-healing at 12 months was observed in 10/29 (34%) patients overall, and in 3/14 (21%) when therapy started within three weeks following the index operation. Major LARS was reported in 12/15 (80%) patients. The direct medical costs were €8933 (95% CI 7268–10,707) per patient. Conclusion Vacuum-assisted early transanal closure of a leaking anastomosis after total mesorectal excision with 73% preoperative radiotherapy showed that acceptable anastomotic healing rates and stoma reversal rates can be achieved. Early diagnosis and start of treatment seems crucial.
Collapse
Affiliation(s)
- W A A Borstlap
- Department of Surgery, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, The Netherlands.
| | - G D Musters
- Department of Surgery, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, The Netherlands
| | - L P S Stassen
- Department of Surgery, Academic Hospital Maastricht, Maastricht, The Netherlands
| | | | - D Hess
- Department of Surgery, Antonius Zorggroep, Sneek, The Netherlands
| | - S van Dieren
- Department of Surgery, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, The Netherlands
| | - S Festen
- Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
| | - E J van der Zaag
- Department of Surgery, Gelre Ziekenhuis, Apeldoorn, The Netherlands
| | - P J Tanis
- Department of Surgery, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, The Netherlands
| | - W A Bemelman
- Department of Surgery, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, The Netherlands
| |
Collapse
|
16
|
Bakker IS, Morks AN, ten Cate Hoedemaker HO, Burgerhof JGM, Leuvenink HG, van Praagh JB, Ploeg RJ, Havenga K, Bakker IS, Morks AN, ten Cate Hoedemaker HO, Leuvenink HG, Ploeg RJ, Havenga K, van Etten B, Lange JFM, Hemmer PHJ, Burgerhof JGM, Sonneveld DJA, Tanis PJ, Wegdam JA, Jonk A, Lutke Holzik MF, Bosker RJI, Lamme B, Spillenaar Bilgen EJ, Bremers AJ, van der Mijle HC, Hoff C, de Vries DP, Logeman F, Sietses C, Lesanka Versluijs-Ossewaarde FN, Leijtens JW, Tobon Morales RE, Neijenhuis PA, Kloppenberg FW, Schasfoort R, Bleeker WA, Hess D, Rosman C, Wit F, Ton van Engelenburg KC, Pronk A, Bonsing BA, Dekker JW, Consten EC, Patijn GA, Bogdan Rajcs S, Csapó Z, Bálint A, Harsányi L, István G, Horisberger K, Bader F, Kutup A, Mariette C, Cebrián F. Randomized clinical trial of biodegradeable intraluminal sheath to prevent anastomotic leak after stapled colorectal anastomosis. Br J Surg 2017; 104:1010-1019. [DOI: 10.1002/bjs.10534] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 06/09/2016] [Accepted: 02/08/2017] [Indexed: 12/11/2022]
Abstract
Abstract
Background
Anastomotic leakage is a potential major complication after colorectal surgery. The C-seal was developed to help reduce the clinical leakage rate. It is an intraluminal sheath that is stapled proximal to a colorectal anastomosis, covering it intraluminally and thus preventing intestinal leakage in case of anastomotic dehiscence. The C-seal trial was initiated to evaluate the efficacy of the C-seal in reducing anastomotic leakage in stapled colorectal anastomoses.
Methods
This RCT was performed in 41 hospitals in the Netherlands, Germany, France, Hungary and Spain. Patients undergoing elective surgery with a stapled colorectal anastomosis less than 15 cm from the anal verge were eligible. Included patients were randomized to the C-seal and control groups, stratified for centre, anastomotic height and intention to create a defunctioning stoma. Primary outcome was anastomotic leakage requiring invasive treatment.
Results
Between December 2011 and December 2013, 402 patients were included in the trial, 202 in the C-seal group and 200 in the control group. Anastomotic leakage was diagnosed in 31 patients (7·7 per cent), with a 10·4 per cent leak rate in the C-seal group and 5·0 per cent in the control group (P = 0·060). Male sex showed a trend towards a higher leak rate (P = 0·055). Construction of a defunctioning stoma led to a lower leakage rate, although this was not significant (P = 0·095).
Conclusion
C-seal application in stapled colorectal anastomoses does not reduce anastomotic leakage. Registration number: NTR3080 (http://www.trialregister.nl/trialreg/index.asp).
Collapse
Affiliation(s)
- I S Bakker
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - A N Morks
- Department of Surgery, Groene Hart Ziekenhuis, Gouda, The Netherlands
| | - H O ten Cate Hoedemaker
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - J G M Burgerhof
- Departments of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - H G Leuvenink
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - J B van Praagh
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - R J Ploeg
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
| | - K Havenga
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - I S Bakker
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - A N Morks
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - H O ten Cate Hoedemaker
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - H G Leuvenink
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - R J Ploeg
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - K Havenga
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - B van Etten
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - J F M Lange
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - P H J Hemmer
- Departments of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - J G M Burgerhof
- Departments of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | | | - P J Tanis
- Academic Medical Centre, Amsterdam, The Netherlands
| | - J A Wegdam
- Elkerliek Ziekenhuis, Helmond, The Netherlands
| | - A Jonk
- Streekziekenhuis Koningin Beatrix, Winterswijk, The Netherlands
| | | | | | - B Lamme
- Albert Schweitzer Hospital, Dordrecht, The Netherlands
| | | | - A J Bremers
- Radboud University, Nijmegen Medical Centre, The Netherlands
| | | | - C Hoff
- Medical Centre, Leeuwarden, The Netherlands
| | - D P de Vries
- Ommelander Ziekenhuis Group, Winschoten, The Netherlands
| | - F Logeman
- Beatrix Hospital, Gorinchem, The Netherlands
| | - C Sietses
- Gelderse Vallei Hospital, Ede, The Netherlands
| | | | | | | | | | | | | | | | - D Hess
- Antonius Hospital, Sneek, The Netherlands
| | - C Rosman
- Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| | - F Wit
- Tjongerschans Hospital, Heerenveen, The Netherlands
| | | | - A Pronk
- Diakonessenhuis, Utrecht, The Netherlands
| | - B A Bonsing
- Leiden University Medical Centre, The Netherlands
| | - J W Dekker
- Reinier de Graaf Hospital, Delft, The Netherlands
| | - E C Consten
- Meander Medical Centre, Amersfoort, The Netherlands
| | | | - S Bogdan Rajcs
- Szabolcs-Szatmár-Bereg County Hospitals, Jósa András University Teaching Hospital, Nyíregyháza, Hungary
| | - Z Csapó
- Flór Ferenc Hospital of County Pest, Kistarcsa, Hungary
| | - A Bálint
- Szent Imre Hospital, Budapest, Hungary
| | - L Harsányi
- Semmelweis University, First Department of surgery, Budapest, Hungary
| | - G István
- Semmelweis University, Second Department of Surgery, Budapest, Hungary
| | - K Horisberger
- University Medical Centre Mannheim, University of Heidelberg, Germany
| | - F Bader
- Klinikum Rechts der Isar, Technische Universität München, Germany
| | - A Kutup
- University Medical Centre Hamburg–Eppendorf, Germany
| | - C Mariette
- Claude Huriez University Hospital, Lille, France
| | - F Cebrián
- Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | | |
Collapse
|
17
|
Kfoury E, Hess D, Luerman G, Guenther E, Bohlen H. Human iPSC derived neurons recorded by MEA technology: A powerful tool for functional assessment of in vitro neurotoxicity and network activity. J Pharmacol Toxicol Methods 2017. [DOI: 10.1016/j.vascn.2017.02.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Ann Oncol 2017; 28:305-312. [DOI: 10.1093/annonc/mdw622] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Herengt F, Pernot J, Camara B, Pison C, Hess D, Aguilaniu B. Le tabagisme actif des patients BPCO légers (VEMS>70 %) accentue-t-il les symptômes, la fréquence des exacerbations et l’engagement dans les activités physiques quotidiennes ? Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Quétant S, Marquette C, Leroy S, Pradelli J, Lintz F, Prévot G, Hess D, Aguilaniu B. La confirmation d’un diagnostic de fibrose pulmonaire idiopathique implique-t-elle la prescription immédiate d’un traitement antifibrosant ? Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Kelkel É, Andujar P, Bon F, Lorillou M, Hess D, Aguilaniu B. Caractéristiques des patients BPCO Gold I–II selon qu’ils sont traités ou non par association fixe. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Quétant S, Hess D, Membres de L’ACCP, Aguilaniu B. Colibri-PID : observatoire Web pour faciliter le cheminement diagnostic et le suivi des pneumopathies interstitielles diffuses (PID). Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
23
|
Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). Br J Clin Pharmacol 2015; 80:128-38. [PMID: 25580946 DOI: 10.1111/bcp.12583] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 12/08/2014] [Accepted: 12/31/2014] [Indexed: 11/30/2022] Open
Abstract
AIMS Namitecan is a new camptothecan compound undergoing early clinical development. This study was initiated to build an integrated pharmacokinetic (PK) and pharmacodynamic (PD) population model of namitecan to guide future clinical development. METHODS Plasma concentration-time data, neutrophils and thrombocytes were pooled from two phase 1 studies in 90 patients with advanced solid tumours, receiving namitecan as a 2 h infusion on days 1 and 8 every 3 weeks (D1,8) (n = 34), once every 3 weeks (D1) (n = 29) and on 3 consecutive days (D1-3) (n = 27). A linear three compartment PK model was coupled to a semiphysiological PD-model for neutrophils and thrombocytes. Data simulations were used to interrogate various dosing regimens and give dosing recommendations. RESULTS Clearance was estimated to be 0.15 l h(-1), with a long terminal half-life of 48 h. Body surface area was not associated with clearance, supporting flat-dosing of namitecan. A significant and clinically relevant association was found between namitecan area under the concentration-time curve (AUC) and the percentage drop of neutrophils (r(2) = 0.51, P < 10(-4)) or thrombocytes (r(2) = 0.49, P < 10(-4)). With a target for haematological dose-limiting toxicity of <20%, the recommended dose was defined as 12.5 mg for the D1,8 regimen, 23 mg for the once every 3 week regimen and 7 mg for the D1-3 regimen. CONCLUSION This is the first integrated population PK-PD analysis of the new hydrophilic topoisomerase I inhibitor namitecan, that is currently undergoing early clinical development. A distinct relationship was found between drug exposure and haematological toxicity, supporting flat-dosing once every 3 weeks as the most adequate dosing regimen.
Collapse
Affiliation(s)
- M Joerger
- Department of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland.,Clinical Research Facility, Department of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland
| | - D Hess
- Department of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland.,Clinical Research Facility, Department of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland
| | - A Delmonte
- European Institute of Oncology, Milan, Italy
| | - E Gallerani
- IOSI Oncology Insitute of Southern Switzerland, Bellinzona, Switzerland
| | - A Fasolo
- Department of Medical Oncology, Ospedale San Raffaele, IRCCS, Scientific Institute, Milan, Italy
| | - L Gianni
- Department of Medical Oncology, Ospedale San Raffaele, IRCCS, Scientific Institute, Milan, Italy
| | - S Cresta
- IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - P Barbieri
- Sigma-Tau Research Switzerland S.A., Mendrisio, Switzerland
| | - S Pace
- Sigma-Tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - C Sessa
- IOSI Oncology Insitute of Southern Switzerland, Bellinzona, Switzerland
| |
Collapse
|
24
|
Nikolajeva O, Mijovic A, Hess D, Tatam E, Amrolia P, Chiesa R, Rao K, Silva J, Veys P. Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience. Bone Marrow Transplant 2015; 50:846-9. [DOI: 10.1038/bmt.2015.53] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2014] [Revised: 02/11/2015] [Accepted: 02/13/2015] [Indexed: 11/09/2022]
|
25
|
Porro M, Sharma S, Witteveen P, Lolkema M, Hess D, Gelderblom H, Hussain S, Waldron E, Valera S, Mu S. 572 Oral panobinostat in patients with advanced tumors and impaired renal function: Relationship between pharmacokinetics and key safety parameters. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70698-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
|
27
|
|
28
|
|
29
|
Aguilaniu B, Kelkel E, Hess D, Herengt F, Ben Saidane H, Guillaud-Segard B, Gonzalez-Bermejo J, Bertrand D, Camara B, Pernot J, Pison C, Pépin JL. COLIBRI-BPCO : observatoire longitudinal basé sur une consultation-web pour les pneumologues hospitaliers (H) et libéraux (L). Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Joiner DM, Less KD, Van Wieren EM, Hess D, Williams BO. Heterozygosity for an inactivating mutation in low-density lipoprotein-related receptor 6 (Lrp6) increases osteoarthritis severity in mice after ligament and meniscus injury. Osteoarthritis Cartilage 2013; 21:1576-85. [PMID: 23756208 DOI: 10.1016/j.joca.2013.05.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2013] [Revised: 05/30/2013] [Accepted: 05/31/2013] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Wnt/β-catenin signaling plays an integral and complex role in cartilage development and maintenance. β-catenin signaling has been linked to osteoarthritis (OA), but the role of Lrp6-mediated Wnt/β-catenin signaling during OA remains unexplored. Mutations in the Wnt/β-catenin co-receptors LRP5 and LRP6 (low-density lipoprotein-related receptors 5 and 6) result in skeletal abnormalities, which tend to be more severe in Lrp6 mutant mice. We examined OA development, chondrocyte and osteoblast behavior, and β-catenin signaling after ligament and meniscus damage in mice with global heterozygous deletion of Lrp6. DESIGN Ligament and meniscus damage was surgically induced in Lrp6(+/-) and wild-type (WT) mice, and evidence of joint disease was assessed by Microcomputed tomography (micro-CT) and histology. Wnt/β-catenin signaling, proliferation, apoptosis, chondrogenesis, osteogenesis, and catabolic enzyme activity were measured. RESULTS Relative to WT mice, Lrp6(+/-) mice had lower nuclear β-catenin signaling within articular cartilage. After surgery, osteophytes and reduced articular cartilage were apparent in WT mice, but more severe in Lrp6(+/-) animals. Impairments to trabecular bone geometry occurred for WT and Lrp6(+/-) mice after surgery. Relative to WT mice, Lrp6(+/-) mice had reduced trabecular BMD and thickness, and Cyclin D1 and Lrp6 gene expression after surgery. There was an increase in apoptotic cells and serum matrix metalloproteinase-9 (MMP9) for Lrp6(+/-) mice after surgery, but no differences in cell proliferation occurred. CONCLUSIONS Heterozygous loss-of-function mutation in Lrp6 leads to less β-catenin signaling within articular cartilage and to increased degenerative joint disease after ligament and meniscus injury. Modulation of Lrp6 function could attenuate joint disease after damage to ligaments and the meniscus.
Collapse
Affiliation(s)
- D M Joiner
- Center for Skeletal Disease Research, Van Andel Research Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503, USA.
| | | | | | | | | |
Collapse
|
31
|
Espinosa K, Gerrity J, Pandori M, Marsiglia V, Hardick J, Barnes M, Hess D, Gaydos C. O03.6 Using Molecular Typing to Investigate N. Gonorrhoeae Strain Turnover: A Comparative Study of GISP Isolates Collected from Baltimore and San Francisco. Br J Vener Dis 2013. [DOI: 10.1136/sextrans-2013-051184.0100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Elmer J, Hou P, Wilcox S, Chang Y, Bajwa E, Hess D, Camargo C, Greenberg S, Rosand J, Pallin D, Goldstein J. 47 EMF Risk of Acute Lung Injury After Spontaneous Intracerebral Hemorrhage. Ann Emerg Med 2012. [DOI: 10.1016/j.annemergmed.2012.06.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Dirix L, Schuler M, Machiels J, Hess D, Awada A, Steeghs N, Paz-Ares L, von Moos R, Rabault B, Rodon J. Phase IB Dose-Escalation Study of BEZ235 or BKM120 in Combination with Paclitaxel (PTX) in Patients With Advanced Solid Tumors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33012-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
34
|
Fasolo A, Del Conte G, Calderone RG, Gallerani E, Hagner N, Barbieri P, Luraghi L, Pace S, Capocasa F, Coceani N, Maccioni E, Hess D, Sessa C, Gianni L. Phase I clinical trial of namitecan (ST1968): Results with D1-3 q3wks schedule. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13570] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Gross S, Lennerz V, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. First-in-human trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine EMD640744. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2515] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Abstract
AbstractWe simulate the microscopic details of brittle fracture in silicon by dynamically coupling empirical-potential molecular dynamics of a strained sample to a quantum-mechanical description of interatomic bonding at the crack tip. Our simulations show brittle fracture at loads comparable to experiment, in contrast with empirical potential simulations that show only ductile crack propagation at much higher loading. While the ductility of the empirical potentials can be attributed to their short range, it is unclear whether the increased range of the tight-binding description is sufficient to explain its brittle behavior. Using the multiscale method we show that at a temperature of 1100 K, but not at 900 K, a dislocation is sometimes nucleated when the crack tip impinges on a vacancy. While this result is too limited in length and time scales to directly correspond to experimental observations, it is suggestive of the experimentally observed brittle to ductile transition.
Collapse
|
37
|
Sessa C, Martinelli G, Hess D, Delmonte A, Noberasco C, Sammassimo S, Gallerani E, Marsoni S, Camboni G, de Braud F. 379 A first in human phase I study of the proteasome inhibitor CEP-18770 in patients (pts) with advanced solid tumors, non-Hodgkin's lymphomas (NHL) and multiple myeloma (MM). EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72086-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
38
|
Fasolo A, Sessa C, Bauer JA, Hess D, Viganò L, Del Conte G, Capri G, Gibson D, Ruiz-Soto R, Gianni L. Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Hess D, Papp H, Baerns M. Fe/Mn Oxide Catalysts for Fischer-Tropsch-Synthesis Part VII: Adsorption of Carbon Monoxide and Nitrogen at Low Temperatures. ACTA ACUST UNITED AC 2010. [DOI: 10.1002/bbpc.19860901222] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
40
|
Hawle H, Hess D, Mueller A, Thuerlimann B. Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Rep Oncol 2010; 3:131-136. [PMID: 20740185 PMCID: PMC2919988 DOI: 10.1159/000313838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies. Complete remission was achieved with full dose and maintained even after dose reduction due to unanticipated intensity of mucosal toxicity. Complete remission was temporarily lost after fulvestrant was tentatively withdrawn (63 months after treatment start), but was re-achieved after renewal of half-dose treatment and last reconfirmed 90 months after treatment start. The pharmacokinetic profile provides evidence to hypothesize a unique sensitivity to fulvestrant in this patient which might explain both: toxicity and extraordinary efficacy.
Collapse
Affiliation(s)
- H. Hawle
- Department of Medical Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - D. Hess
- Department of Medical Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - A. Mueller
- Department of Medical Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
- Department of Medical Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland
| | - B. Thuerlimann
- Breast Center, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| |
Collapse
|
41
|
Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene 2010; 29:3554-65. [PMID: 20400976 DOI: 10.1038/onc.2010.115] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Protein kinase B (PKB/Akt) is ubiquitously expressed in cells. Phosphorylation of its multiple targets in response to various stimuli, including growth factors or cytokines, promotes cell survival and inhibits apoptosis. PKB is upregulated in many different cancers and a significant amount of the enzyme is present in its activated form. Here we show that PKB phosphorylates one of the anti-apoptotic proteins--transcription factor Twist-1 at Ser42. Cells expressing Twist-1 displayed inefficient p53 upregulation in response to DNA damage induced by gamma-irradiation or the genotoxic drug adriamycin. This influenced the activation of p53 target genes such as p21(Waf1) and Bax and led to aberrant cell-cycle regulation and the inhibition of apoptosis. The impaired induction of these p53 effector molecules is likely to be mediated by PKB-dependent phosphorylation of Twist-1 because, unlike the wild-type mutant, the Twist-1 S42A mutant did not confer cell resistance to DNA damage. Moreover, phosphorylation of Twist-1 at Ser42 was shown in vivo in various human cancer tissues, suggesting that this post-translational modification ensures functional activation of Twist-1 after promotion of survival during carcinogenesis.
Collapse
Affiliation(s)
- A Vichalkovski
- Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, Basel, Switzerland
| | | | | | | | | |
Collapse
|
42
|
Kelley AJ, Yang L, Hess D, Yin V, Dagnelie G. Comparison of presentation modes for reading and face recognition in simulated prosthetic vision. J Vis 2010. [DOI: 10.1167/3.12.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
43
|
|
44
|
Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. Gerontology 2009; 56:303-9. [PMID: 19940466 DOI: 10.1159/000262450] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2009] [Accepted: 09/07/2009] [Indexed: 11/19/2022] Open
Abstract
Angiogenesis is essential for normal tissue and even more so for solid malignancies. At present, inhibition of tumor angiogenesis is a major focus of anticancer drug development. Bevacizumab, a humanized antibody against VEGF, was the first antiangiogenic agent to be approved for advanced non-small cell lung cancer, breast cancer and colorectal cancer. The most commonly observed adverse events are hypertension, proteinuria, bleeding and thrombosis. Sunitinib, a small molecule blocking intracellular VEGF, KIT, Flt3 and PDGF receptors, which regulate angiogenesis and cell growth, is approved for the treatment of advanced renal cell cancer (RCC) and malignant gastrointestinal stromal tumor. The most frequent adverse events include hand-foot syndrome, stomatitis, diarrhea, fatigue, hypothyroidism and hypertension. Sorafenib, an oral multikinase inhibitor, is approved for the second-line treatment of advanced RCC and upfront treatment of advanced hepatocellular carcinoma. Most common adverse events with sorafenib are dermatologic (hand-foot skin reaction, rash, desquamation), fatigue, diarrhea, nausea, hypothyroidism and hypertension. More recently, cardiovascular toxicity has increasingly been recognized as a potential adverse event associated with sunitinib and sorafenib treatment. Elderly patients are at increased risk of thromboembolic events when receiving bevacizumab, and potentially for cardiac dysfunction when receiving sunitinib or sorafenib. The safety of antiangiogenic drugs is of special concern when taking these agents for longer-term adjuvant or maintenance treatment. Furthermore, newer investigational antiangiogenic drugs are briefly reviewed.
Collapse
Affiliation(s)
- S Boehm
- Department of Oncology and Hematology, Cantonal Hospital, St. Gallen, Switzerland
| | | | | | | |
Collapse
|
45
|
Sessa C, Tosi D, Viganò L, Albanell J, Hess D, Maur M, Cresta S, Locatelli A, Angst R, Rojo F, Coceani N, Rivera VM, Berk L, Haluska F, Gianni L. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol 2009; 21:1315-1322. [PMID: 19901013 DOI: 10.1093/annonc/mdp504] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The additive cytotoxicity in vitro prompted a clinical study evaluating the non-prodrug rapamycin analogue ridaforolimus (AP23573; MK-8669; formerly deforolimus) administered i.v. combined with paclitaxel (PTX; Taxol). MATERIALS AND METHODS Patients with taxane-sensitive solid tumors were eligible. The main dose escalation foresaw 50% ridaforolimus increments from 25 mg with a fixed PTX dose of 80 mg/m(2), both given weekly 3 weeks in a 4-week cycle. Collateral levels with a lower dose of either drug were planned upon achievement of the maximum tolerated dose in the main escalation. Pharmacodynamic studies in plasma, peripheral blood mononuclear cells (PBMCs) and skin biopsies and pharmacokinetic (PK) interaction studies at cycles 1 and 2 were carried out. RESULTS Two recommended doses were determined: 37.5 mg ridaforolimus/60 mg/m(2) PTX and 12.5 mg/80 mg/m(2). Most frequent toxic effects were mouth sores (79%), anemia (79%), fatigue (59%), neutropenia (55%) and dermatitis (48%). Two partial responses were observed in pharyngeal squamous cell and pancreatic carcinoma. Eight patients achieved stable disease > or =4 months. No drug interaction emerged from PK studies. Decrease of eukaryotic initiation factor 4E-binding protein1 (4E-BP1) phosphorylation was shown in PBMCs. Similar inhibition of phosphorylation of 4E-BP1 and mitogen-activated protein kinase was present in reparative epidermis and vascular tissues, respectively. CONCLUSION Potential antiangiogenic effects and encouraging antitumor activity justify further development of the combination.
Collapse
Affiliation(s)
- C Sessa
- Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Department of Medical Oncology I, 'Montabone' Unit for New Drug Development, Fondazione IRCCS Istituto dei Tumori di Milano, Italy
| | - D Tosi
- Department of Medical Oncology I, 'Montabone' Unit for New Drug Development, Fondazione IRCCS Istituto dei Tumori di Milano, Italy
| | - L Viganò
- Department of Medical Oncology I, 'Montabone' Unit for New Drug Development, Fondazione IRCCS Istituto dei Tumori di Milano, Italy
| | - J Albanell
- Department of Medical Oncology, IMAS-Hospital del Mar, Barcelona, Spain
| | - D Hess
- Department of Oncology-Hematology, Kantonsspital St. Gallen, Saint Gallen, Switzerland
| | - M Maur
- Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - S Cresta
- Department of Medical Oncology I, 'Montabone' Unit for New Drug Development, Fondazione IRCCS Istituto dei Tumori di Milano, Italy
| | - A Locatelli
- Department of Medical Oncology I, 'Montabone' Unit for New Drug Development, Fondazione IRCCS Istituto dei Tumori di Milano, Italy
| | - R Angst
- Department of Oncology-Hematology, Kantonsspital St. Gallen, Saint Gallen, Switzerland
| | - F Rojo
- Molecular Therapeutics and Biomarkers in Breast Cancer Program, IMIM-Hospital del Mar, Barcelona, Spain
| | - N Coceani
- Study Management Unit, Southern Europe New Drugs Organization, Milano, Italy
| | - V M Rivera
- Preclinical and Translational Research Unit
| | - L Berk
- Preclinical and Translational Research Unit
| | - F Haluska
- Clinical Research Unit, ARIAD Pharmaceuticals Inc., Cambridge, MA, USA
| | - L Gianni
- Department of Medical Oncology I, 'Montabone' Unit for New Drug Development, Fondazione IRCCS Istituto dei Tumori di Milano, Italy.
| |
Collapse
|
46
|
Hess D, Boehm S, Delmonte A, Gallerani E, Barbieri P, Pace S, Carminati P, Marsoni S, Coceani N, Sessa C. Clinical development of namitecan (ST1968), a novel camptothecin derivative with high antitumor activity: Phase I clinical data. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2570] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2570 Background: Namitecan is a new water-soluble camptothecin analogue which showed high antitumor activity in preclinical models. Aim of this trial was to determine safety, PK profile and activity in adult patients with advanced solid tumors. Methods: The dose escalation started at 2.5 mg i.v. on days 1 and 8 of a 21 day cycle (D1, D8 Q21D) and increased according to 3+3 cohort design depending on the observed toxicity. Dose limiting toxicity (DLT) definitions were: ANC <0.5x109/L for >5 days; PLT ≥ Grade 3 (CTC V3); grade ≥2 liver/renal toxicity not recovered by D22; any non-hematologic toxicity ≥ Grade 3; D8 dose skipping due to toxicity. Maximum tolerated dose (MTD) and recommended dose (RD) were the primary end-points. Blood and urine samples were collected at cycle 1 for PK evaluation. Results: 31 pts (11 endometrial ca., 5 CRC, 5 ovarian ca., 2 NSCLC, 8 other) have been included, with 6 dose levels evaluated (2.5; 5; 10; 15; 17.5 and 20 mg). 17.5 mg was introduced later when 2/7 DLTs at 20 mg were observed (ANC G4>5days, one with D8 skipping). At 17.5mg 2/4 pts experienced DLTs (ANC G4; D8 skipped). Uncomplicated neutropenia and thrombocytopenia were the most relevant G3/4 hematological toxicities. Other toxicities were mild or moderate asthenia, fatigue and alopecia. The MTD was defined at 17.5 mg and the RD was 15 mg. Stable disease ≥ 6 cycles was recorded in 6 pts (2 stable diseases ≥ 10 cycles). PK was linear and data suggest an entero-hepatic recirculation. No metabolites were found in plasma and the product resulted poorly excreted into urine. Conclusions: The MTD and RD of D1, D8 Q21D schedule have been identified. The study will continue with the evaluation of MTD and RD of a single administration per cycle (D1 Q21D), to optimize the schedule of treatment. [Table: see text]
Collapse
Affiliation(s)
- D. Hess
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - S. Boehm
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - A. Delmonte
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - E. Gallerani
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - P. Barbieri
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - S. Pace
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - P. Carminati
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - S. Marsoni
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - N. Coceani
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - C. Sessa
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| |
Collapse
|
47
|
Gresko E, Ritterhoff S, Sevilla-Perez J, Roscic A, Fröbius K, Kotevic I, Vichalkovski A, Hess D, Hemmings BA, Schmitz ML. PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage. Oncogene 2008; 28:698-708. [PMID: 19015637 DOI: 10.1038/onc.2008.420] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The promyelocytic leukemia (PML) tumor suppressor protein, a central regulator of cell proliferation and apoptosis, is frequently fused to the retinoic acid receptor-alpha (RARalpha) in acute PML. Here we show the interaction of PML with another tumor suppressor protein, the serine/threonine kinase homeodomain-interacting protein kinase (HIPK2). In response to DNA damage, HIPK2 phosphorylates PML at serines 8 and 38. Although HIPK2-mediated phosphorylation of PML occurs early during the DNA damage response, the oncogenic PML-RARalpha fusion protein is phosphorylated with significantly delayed kinetics. DNA damage or HIPK2 expression leads to the stabilization of PML and PML-RARalpha proteins. The N-terminal phosphorylation sites contribute to the DNA damage-induced PML SUMOylation and are required for the ability of PML to cooperate with HIPK2 for the induction of cell death.
Collapse
Affiliation(s)
- E Gresko
- Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Rinaldi A, Kwee I, Bertoni F, Viganò L, Hess D, Coceani N, Sessa C, Rivera V, Bedrosian C, Catapano C. 195 POSTER Pharmacogenomic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK 8669) in phase Ib studies. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72127-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
49
|
Scambia G, Parma G, Del Conte G, Hess D, Gadducci A, Katsaros D, Sessa C, Trudel GC, Coceani N, Colombo N. A phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5581] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Sessa C, Hess D, Bauer J, Droege C, Gallerani E, Miani M, Tinazzi A, Krieter O, Angst R, Nay C. Phase I study of the oral platinum agent satraplatin (S) in sequential combination with capecitabine (C) in patients with advanced solid tumours. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2560] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|